Can I take magnesium glycinate and ashwagandha for perimenopause sleep? I'm on an SSRI.
⚠ Safety first
[why?]
This was promoted by the safety gate because the interaction edge between the intervention and an item in your context fires at moderateseverity. Safety items are ordered most-severe-first; nothing else displaces them.
[how serious?]
Possible additive or interfering effect; evidence is limited. Worth a clinician check before combining.
This case routes to a clinician because the combination touches a prescription in your context — the engine will not silently recommend it.
For your question
modest improvement in sleep
[see studies]
The grade (grade B) reflects the combined weight of these sources; certainty (moderate) is the engine's separate read on how confident to be — never the same thing.
Okafor J, Lindqvist M. Magnesium supplementation and sleep: a systematic review of RCTs. Journal of Sleep Research (2024) · peer-reviewed · Karolinska Institutet · PMID:00000001small, early-stage effect on sleep
[see studies]
The grade (grade C) reflects the combined weight of these sources; certainty (low) is the engine's separate read on how confident to be — never the same thing.
Ashwagandha for sleep: small RCTs · PMID:00000002People say · Evidence shows
“Magnesium glycinate is better for sleep because it crosses the blood-brain barrier”
[explain]
popularity / assertion runs ahead of the evidence.
Belief direction is the position of the belief relative to the evidence; magnitude combines the grade-distance, whether the evidence state is unflattering to the assertion, and the claim-type penalty for speculation or marketing language (rubric: Doc 17 §2.3).
The belief never inherits the evidence's grade — by axiom B4. Speculation that outruns the data does not get credit for the data.
“Ashwagandha balances cortisol”
[explain]
popularity / assertion runs ahead of the evidence.
Belief direction is the position of the belief relative to the evidence; magnitude combines the grade-distance, whether the evidence state is unflattering to the assertion, and the claim-type penalty for speculation or marketing language (rubric: Doc 17 §2.3).
The belief never inherits the evidence's grade — by axiom B4. Speculation that outruns the data does not get credit for the data.
What the label may legally say
“Helps the body adapt to stress”
“Supports muscle and nerve function”
A legal label claim — it does not have to be proven and is not the same as evidence. We keep “people say,” “the law permits,” and “the evidence shows” visibly separate.
Trending?
magnesium — evidence and attention roughly aligned · ashwagandha — attention is ahead of the evidence
[hype vs evidence]
The hype position is the L4 read: where an intervention sits on the emerging → settled → debunked arc. A surging position with thin evidence is the classic gap; a settled position with B-grade evidence means attention and proof are roughly aligned.
What I don't know about you
- which specific SSRI and dose
- other medications or conditions
- your sleep history
Knowing these would sharpen the safety check and the answer. They're session-scoped only — never stored as a profile.
Making your decision
If you want to try the better-supported options:
- Magnesium (glycinate) — 200–400 mg, glycinate, adults; Generally fine with an SSRI; space about 2 hours apart.
Here’s what would change this advice: which specific SSRI and dose · other medications or conditions · your sleep history.
This is information to support your decision — not a verdict, and not a substitute for your clinician.
Why am I seeing this?
The reasoning trace — the discrete steps the composition engine took (Doc 03, Doc 05 §5.1). Nothing was inferred outside this list.
- resolve: interventions=[mg, ash] outcome=sleep lifeStage=perimenopause meds=[ssri]
- retrieve: 2 evidence claim(s)
- contrast: 2 belief(s) with computed gaps
- safety-gate: 1 promoted; blocklist=[none]
- time: {"Magnesium":"settled","Ashwagandha":"surging"}
- law-permits: 2 label claim(s)
model slice-0.1.0 · as of 2026-06-04T15:20:28.010Z